Ý nghĩa tiên lượng của dephospho-uncarboxylated Matrix Gla-Protein trong suy tim: Những hiểu biết về xơ vữa mạch máu và ý nghĩa điều trị

Highlights

• Dephospho-uncarboxylated matrix Gla-protein (dpucMGP) is a significant independent predictor of all-cause mortality and heart failure (HF)-related hospitalizations.
• Higher levels of dpucMGP significantly mediate the association between warfarin use and adverse clinical outcomes in heart failure populations.
• Extensive proteomic analysis links dpucMGP to multiple systemic pathways, including acute-phase response, coagulation, complement activation, and fibrosis.
• The prognostic value of dpucMGP appears particularly pronounced in patients with nonischemic heart failure.

Background

Matrix Gla-protein (MGP) is a potent endogenous inhibitor of vascular calcification. Synthesized primarily by vascular smooth muscle cells and chondrocytes, its biological activity is strictly dependent on a post-translational modification process involving vitamin K-dependent carboxylation of glutamate residues. In states of vitamin K deficiency or pharmacological inhibition (such as with vitamin K antagonists like warfarin), MGP remains in its inactive, uncarboxylated form, known as dephospho-uncarboxylated matrix Gla-protein (dpucMGP).

While previous research has established that elevated circulating dpucMGP levels correlate with large artery stiffening and sarcopenia (reduced skeletal muscle mass) in heart failure (HF) patients, its definitive association with long-term clinical outcomes—specifically mortality and hospitalization—has remained an area of active investigation. Understanding the role of dpucMGP is particularly critical given the prevalence of atrial fibrillation in HF patients, which often necessitates anticoagulation, traditionally managed with warfarin.

Key Content

Methodological Framework and Patient Demographics

The pivotal evidence for the prognostic role of dpucMGP comes from a comprehensive cohort study involving 2,247 participants from the Penn Heart Failure Study (PHFS). This population represented a broad spectrum of HF, with a median age of 61 years, a majority of male participants (64%), and a significant representation of White (71%) and Black (ethnicity-specific findings were notable) individuals. The researchers utilized the high-sensitivity SomaScan assay to measure dpucMGP and approximately 5,000 other proteins, allowing for an unprecedented look at the proteomic correlates of this biomarker.

Proteomic Associations and Biological Pathways

One of the most significant findings of the PHFS analysis was the discovery of extensive proteomic associations with dpucMGP. Elevated levels were not isolated but were part of a larger systemic shift in biological signaling. Significant correlations were identified in the following domains:

• Acute Phase Response and Inflammation: dpucMGP levels were associated with markers of systemic inflammation, suggesting a link between vascular health and chronic inflammatory states in HF.
• Coagulation and Complement System: The association with coagulation factors and the complement cascade underscores the role of MGP in the broader context of vascular homeostasis and immune response.
• Fibrosis: Proteomic signatures related to extracellular matrix remodeling and fibrosis were prominent, providing a potential mechanistic link to the structural cardiac changes seen in progressing heart failure.
• Metabolic Pathways: Connections to cell signaling and metabolic regulation were also identified, suggesting that dpucMGP may be a marker of generalized cellular stress.

Clinical Correlates and Risk Stratification

The study established that dpucMGP levels are not uniform across the HF population. Higher levels were consistently found in patients of older age and those with renal dysfunction. Interestingly, Black ethnicity was associated with lower baseline levels of dpucMGP. However, the most striking clinical correlate was the use of warfarin, which significantly elevated circulating dpucMGP due to the inhibition of MGP carboxylation.

Regarding clinical outcomes, the data revealed a standardized hazard ratio (sHR) of 1.23 (95% CI, 1.17-1.28; P<0.0001) for the composite endpoint of death or HF-related hospital admission. For all-cause death alone, the sHR was even higher at 1.32 (95% CI, 1.25-1.40; P<0.0001). These associations remained robust even after adjusting for traditional risk factors, confirming dpucMGP as an independent prognostic marker.

The Warfarin Mediation Analysis

Perhaps the most clinically transformative finding was the mediation analysis regarding warfarin. It is well-known that warfarin use is sometimes associated with worse outcomes in certain HF subsets. This study found that higher dpucMGP levels effectively mediated the relationship between warfarin use and adverse outcomes. Specifically, for death, the total effect of warfarin had a P-value of 0.005, but the indirect effect (mediated through dpucMGP) was highly significant (P<0.001). This suggests that the detrimental effect of warfarin in this population may be partially driven by its inhibition of the vascular protective functions of MGP.

Expert Commentary

The identification of dpucMGP as a significant prognostic factor in heart failure offers a double-edged sword for clinical practice. On one hand, it provides a valuable tool for risk stratification, particularly in nonischemic heart failure where the predictive value was highest. On the other hand, it raises serious questions about the long-term use of Vitamin K Antagonists (VKAs) like warfarin in patients with existing vascular and cardiac stress.

The biology of MGP as a calcification inhibitor is well-understood, but its systemic proteomic associations revealed here suggest it may also influence fibrosis and inflammation. This broadens our view of MGP from a simple vascular gatekeeper to a central player in the systemic environment of heart failure. The fact that dpucMGP mediates warfarin-related risks provides a strong biological rationale for the preferential use of Direct Oral Anticoagulants (DOACs) in HF patients with atrial fibrillation, as DOACs do not interfere with the MGP carboxylation process.

Furthermore, this research opens the door to nutritional and pharmacological interventions. If dephospho-uncarboxylated MGP is a driver of poor outcomes, would Vitamin K supplementation—which promotes the conversion of dpucMGP to its active form—improve outcomes? While studies like the EAT-Lancet diet evaluation emphasize the general importance of nutrient adequacy for planetary and population health, specific interventions aimed at the Vitamin K-MGP axis in HF patients represent a promising frontier for precision medicine.

Conclusion

Elevated levels of dpucMGP are independently associated with an increased risk of mortality and hospitalization in heart failure. By linking dpucMGP to pathways of fibrosis, inflammation, and coagulation, current research provides a comprehensive view of its role in the pathophysiology of HF. Crucially, the discovery that dpucMGP mediates the adverse effects of warfarin underscores the potential cardiovascular toxicity of vitamin K inhibition in vulnerable populations. Future clinical trials should focus on whether reducing dpucMGP levels—through the transition from warfarin to DOACs or via direct Vitamin K supplementation—can improve the survival and quality of life for patients living with heart failure.

References

• Vidula MK, Schurgers LJ, Zhao L, et al. Dephospho-Uncarboxylated Matrix Gla-Protein Is Associated With Adverse Outcomes in Heart Failure. Circ Heart Fail. 2026 Feb;19(2):e012734. doi: 10.1161/CIRCHEARTFAILURE.124.012734. PMID: 41603031.
• Vermeer C, Schurgers LJ. A comprehensive review of vitamin K and vitamin K antagonists. Hematol Oncol Clin North Am. 2000;14(2):339-353.
• Schurgers LJ, et al. Matrix Gla-protein: the calcification inhibitor in need of vitamin K. Thromb Haemost. 2008;100(4):593-603.